Enables sequence-specific DNA binding activity. Involved in several processes, including positive regulation of cellular response to insulin stimulus; regulation of osteoclast differentiation; and response to estradiol. Predicted to be located in several cellular components, including chromatin; intercellular bridge; and nuclear lumen. Predicted to be active in nucleus. Orthologous to human ESRRA (estrogen related receptor alpha); INTERACTS WITH 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dinitrotoluene.
artemisinin inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and artemisinin inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein] and PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein]]
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ESRRA mRNA and [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of ESRRA promoter
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
carfilzomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and carfilzomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
chlormidazole inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and chlormidazole inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
Diethylstilbestrol binds to and results in decreased activity of ESRRA protein and Diethylstilbestrol inhibits the reaction [ESRRA protein results in increased expression of TFF1 mRNA]
Etoposide inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] and Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein]
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and fenpyroximate inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
fluoxastrobin inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and fluoxastrobin inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
Genistein binds to and results in increased activity of ESRRA protein and Genistein binds to and results in increased activity of ESRRA protein mutant form
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in decreased expression of ESRRA protein] and trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ESRRA protein]
celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein] and PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein]]
kresoxim-methyl inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and kresoxim-methyl inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
PPARGC1A protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of ESRRA mRNA] and PPARGC1A protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of ESRRA protein]
1-Methyl-4-phenylpyridinium results in decreased expression of ESRRA mRNA and 1-Methyl-4-phenylpyridinium results in decreased expression of ESRRA protein
picoxystrobin inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and picoxystrobin inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
pyridaben inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and pyridaben inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
resveratrol inhibits the reaction [Glucose results in decreased expression of ESRRA protein] and SIRT1 protein promotes the reaction [resveratrol results in increased expression of ESRRA mRNA]
Rotenone inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and Rotenone inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
Dinoprostone promotes the reaction [ESRRA protein promotes the reaction [Testosterone results in increased abundance of Estradiol]] and ESRRA protein promotes the reaction [Testosterone results in increased abundance of Estradiol]
Topotecan inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and Topotecan inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
trifloxystrobin inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] and trifloxystrobin inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
The orphan nuclear estrogen receptor-related receptor alpha (ERRalpha) is expressed throughout osteoblast differentiation and regulates bone formation in vitro.
AMP activated protein kinase-alpha2 regulates expression of estrogen-related receptor-alpha, a metabolic transcription factor related to heart failure development.
Effects of estradiol, benzophenone-2 and benzophenone-3 on the expression pattern of the estrogen receptors (ER) alpha and beta, the estrogen receptor-related receptor 1 (ERR1) and the aryl hydrocarbon receptor (AhR) in adult ovariectomized rats.